EASD: Studies slam cardiovascular safety of sulfonylureasOctober 13, 2015DiabetesAcute Coronary SyndromesLipid Disorders
EASD: Alirocumab lipid-lowering benefits extend to patients with high-risk diabetesOctober 1, 2015DiabetesLipid Disorders
Long-acting insulin degludec – and degludec combo drug – win FDA nodSeptember 26, 2015Lipid DisordersDiabetes
EASD: SGLT2 inhibitor empagliflozin cuts CV risk in patients with type 2 diabetesSeptember 18, 2015DiabetesAcute Coronary SyndromesLipid Disorders
Long-acting basal insulin controls HbA1c as well as glargineSeptember 16, 2015DiabetesLipid Disorders
ESC: Alirocumab ‘cures’ heterozygous familial hypercholesterolemiaSeptember 15, 2015Lipid DisordersCAD & Atherosclerosis
ESC: Statins reduce postoperative noncardiac surgery event ratesSeptember 4, 2015Acute Coronary SyndromesLipid DisordersStroke
ESC: MI survival of 40-somethings has improved dramaticallySeptember 1, 2015CAD & AtherosclerosisLipid Disorders
Evolocumab is second PCSK9 inhibitor approved to lower LDL in high-risk patientsAugust 27, 2015Lipid Disorders
Mobile health technology may encourage behavioral changeAugust 13, 2015CAD & AtherosclerosisHypertensionLipid Disorders
Testosterone therapy didn’t boost atherosclerosis over 3 yearsAugust 11, 2015CAD & AtherosclerosisLipid Disorders
Adding ezetimibe to atorvastatin boosts coronary plaque regressionJuly 27, 2015Acute Coronary SyndromesLipid Disorders
